Company

Bio-Thera Solutions

As of the edition of 20 October 2026, Bio-Thera Solutions runs 23 drugs; it is on route A at 3 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

StatusCount
Active6
Went quiet2
Stopped6
Status not established9
Total23

Where it needs a new molecule

Route A at 3 targets, route B at 0 targets.

Three of its 3 rows, by target and route
TargetRoute
TNFRSF4 Tumor necrosis factor receptor superfamily member 4Route A
PDCD1 Programmed cell death protein 1Route A
TACSTD2 Tumor-associated calcium signal transducer 2Route A

All 3 rows on route A or B

In the product

3 company-target rows on route A or B; 0 are not shown here, and no score is.

Where its trials are

  • Skin and connective tissue: 5 trials led
  • Eye: 4 trials led
  • Bones, joints and muscles: 3 trials led